Related Experiment Video
Updated: May 29, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Melanoma vaccines
1Surgery Branch, Tumor Immunology Section, National Institutes of Health/National Cancer Institute, Hatfield Clinical Research Center, Bethesda, MD, USA. JamesYang@mail.nih.gov
Abstract:
There is much renewed activity in the testing of vaccines that target metastatic melanoma, driven by successes in other areas, most notably prostate cancer. Yet, sound evidence that any stand-alone vaccination approach has clinical benefit against melanoma remains lacking. With phase III studies showing no efficacy of promising whole-cell vaccines and heat shock proteins, peptide and dendritic cell vaccines remain the most common approaches. A major obstacle to progress is the lack of any surrogate measures in phase II studies that associate meaningfully with clinical benefit, and this is further complicated by phase III evidence in prostate cancer that immunologic monitoring, tumor response rates, or even times to tumor progression may not accurately predict survival benefit. The area with the most progress has been in combining vaccines with other systemic immunostimulatory agents. Although no vaccine has been found which fulfills the prediction from murine models that they can enhance the efficacy of ipilimumab, combining a peptide vaccination with high-dose interleukin 2 was shown to enhance complete and overall response rates compared with interleukin 2 alone. These promising combinations continue to struggle with the same unresolved issues that have plagued melanoma vaccines from the beginning-what are the best antigens to target, what are the best methods of vaccination, and what constitutes a sufficient immune response to be of value? Virtually no progress has been made toward answering these questions.
Insights
Melanoma vaccines show limited standalone clinical benefit, despite renewed activity. Combining vaccines with other agents, like interleukin-2, shows promise for improving response rates in melanoma treatment.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Renewed interest in melanoma vaccines, inspired by successes in other cancers like prostate cancer.
- Despite significant research, robust evidence for the clinical benefit of standalone melanoma vaccination strategies is still lacking.
- Phase III trials have not demonstrated efficacy for whole-cell or heat shock protein vaccines, with peptide and dendritic cell vaccines being more common.
Purpose of the Study:
- To review the current landscape of melanoma vaccine research and development.
- To identify key challenges and obstacles hindering progress in melanoma vaccine efficacy.
- To explore promising combination strategies and their potential impact on treatment outcomes.
Main Methods:
- Review of phase II and phase III clinical trial data for melanoma vaccines.
- Analysis of surrogate markers and their predictive value for clinical benefit.
- Examination of combination therapies involving vaccines and systemic immunostimulatory agents.
Main Results:
- No standalone melanoma vaccine has demonstrated clear clinical benefit in phase III studies.
- Lack of reliable surrogate markers in phase II studies complicates the assessment of vaccine efficacy.
- Combining peptide vaccination with high-dose interleukin-2 improved response rates compared to interleukin-2 alone.
Conclusions:
- Melanoma vaccine development faces persistent challenges, including identifying optimal antigens and vaccination methods.
- Combination therapies represent a promising avenue, but fundamental questions about immune response value remain unanswered.
- Further research is needed to overcome existing hurdles and establish effective melanoma vaccination strategies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:51Vaccinations
01:21Vaccines
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...